Comparing Catalent (CTLT) and Its Rivals

Catalent (NYSE: CTLT) is one of 103 public companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Catalent to similar businesses based on the strength of its dividends, earnings, institutional ownership, analyst recommendations, risk, profitability and valuation.

Profitability

This table compares Catalent and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Catalent 5.01% 23.97% 5.24%
Catalent Competitors -2,436.30% -70.63% -7.85%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Catalent and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Catalent 0 2 5 0 2.71
Catalent Competitors 873 3797 6772 181 2.54

Catalent presently has a consensus target price of $43.71, suggesting a potential upside of 11.43%. As a group, “Pharmaceuticals” companies have a potential upside of 26.97%. Given Catalent’s competitors higher probable upside, analysts plainly believe Catalent has less favorable growth aspects than its competitors.

Volatility & Risk

Catalent has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, Catalent’s competitors have a beta of 34.11, indicating that their average stock price is 3,311% more volatile than the S&P 500.

Valuation and Earnings

This table compares Catalent and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Catalent $2.08 billion $109.80 million 45.09
Catalent Competitors $8.17 billion $1.09 billion 118.76

Catalent’s competitors have higher revenue and earnings than Catalent. Catalent is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

99.5% of Catalent shares are held by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceuticals” companies are held by institutional investors. 1.7% of Catalent shares are held by company insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Catalent competitors beat Catalent on 7 of the 13 factors compared.

Catalent Company Profile

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.

Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.